Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Research from University of Michigan yields new data on cancer
July 2nd, 2009
"Tetrathiomolybdate (TM) is a novel anticancer and anti-angiogenic agent, which acts through copper chelation and NF-kappa B inhibition. This review summarizes the scientific rationale for the use of TM as an anticancer agent in human studies," scientists writing in the journal Expert Opinion on Investigational Drugs report. "A systematic review of the literature was conducted for the use of TM in cancer including preclinical, animal and human studies. The results of this search are summarized in this review. Copper chelation using TM has demonstrated efficacy in preclinical and animal models as an alternative and novel anti-angiogenic agent. Phase I and 11...
Source: Women's Health Weekly (2009-07-02)
|
